Read by QxMD icon Read

Post chemotherapy cognitive deficit

Terence Ng, Ying Yun Lee, Jung-Woo Chae, Angie Hui Ling Yeo, Maung Shwe, Yan Xiang Gan, Raymond C H Ng, Pat Pak Yan Chu, Chiea Chuen Khor, Han Kiat Ho, Alexandre Chan
BACKGROUND: Preliminary evidence suggests that changes in plasma brain-derived neurotrophic factor (BDNF) levels may contribute to the occurrence of chemotherapy-associated cognitive impairment (CACI), and a previous study suggested that carriers of the BDNF Met homozygous genotype are protected from CACI. METHODS: This multicenter, prospective cohort study involved chemotherapy-receiving early-stage breast cancer (ESBC) patients. Self-perceived cognitive function was longitudinally assessed using the validated FACT-Cog (ver...
December 19, 2017: BMC Cancer
Anna Kovalchuk, Yaroslav Ilnytskyy, Rocio Rodriguez-Juarez, Amanda Katz, David Sidransky, Bryan Kolb, Olga Kovalchuk
A wide array of central nervous system complications, neurological deficits, and cognitive impairments occur and persist as a result of systemic cancer and cancer treatments. This condition is known as chemo brain and it affects over half of cancer survivors. Recent studies reported that cognitive impairments manifest before chemotherapy and are much broader than chemo brain alone, thereby adding in tumor brain as a component. The molecular mechanisms of chemo brain are under-investigated, and the mechanisms of tumor brain have not been analyzed at all...
October 24, 2017: Oncotarget
Lori J Bernstein, Graham A McCreath, Zahra Komeylian, Jill B Rich
Women with breast cancer can experience persisting cognitive deficits post treatment. We conducted a multilevel meta-analysis of cognitive function in survivors treated with chemotherapy (Ch+) to estimate the magnitude of cognitive impairment relative to healthy (HC) and chemo-negative (Ch-) controls. Seventy-two studies published up to October 2016 involving 2939 Ch+ yielded 1594 effect sizes. Ch+ demonstrated overall cognitive impairment in comparison with HC but not with Ch-. Relative to HC, Ch+ showed impairment in attention/concentration, processing speed, language, immediate recall, delayed recall, and executive function...
October 29, 2017: Neuroscience and Biobehavioral Reviews
P Huehnchen, W Boehmerle, A Springer, D Freyer, M Endres
Chemotherapy-induced central nervous system (CNS) neurotoxicity presents an unmet medical need. Patients often report a cognitive decline in temporal correlation to chemotherapy, particularly for hippocampus-dependent verbal and visuo-spatial abilities. We treated adult C57Bl/6 mice with 12 × 20 mg kg(-1) paclitaxel (PTX), mimicking clinical conditions of dose-dense chemotherapy, followed by a pulse of bromodesoxyuridine (BrdU) to label dividing cells. In this model, mice developed visuo-spatial memory impairments, and we measured peak PTX concentrations in the hippocampus of 230 nm l(-1), which was sevenfold higher compared with the neocortex...
August 1, 2017: Translational Psychiatry
Janette L Vardy, Myrle M Stouten-Kemperman, Gregory Pond, Christopher M Booth, Sean B Rourke, Haryana M Dhillon, Anna Dodd, Adrian Crawley, Ian F Tannock
Some women report cognitive impairment after adjuvant chemotherapy (CTh) for breast cancer. Here we explore cognitive function, and underlying mechanisms with blood tests and functional magnetic resonance imaging (fMRI). Women treated for early breast cancer were recruited to three groups based on self-reported cognitive symptoms (CS) using FACT-Cog scores. CTh + CS+ (n = 44) had received chemotherapy and self-reported cognitive symptoms; CTh + CS- (n = 52) had chemotherapy but did not report cognitive problems; CTh- (n = 30) had not received chemotherapy...
May 2, 2017: Brain Imaging and Behavior
Christie Yao, Jill B Rich, Kattleya Tirona, Lori J Bernstein
OBJECTIVE: Women treated with chemotherapy for breast cancer experience subtle cognitive deficits. Research has focused on mean performance level, yet recent work suggests that within-person variability in reaction time performance may underlie cognitive symptoms. We examined intraindividual variability (IIV) in women diagnosed with breast cancer and treated with neoadjuvant chemotherapy. METHODS: Patients (n = 28) were assessed at baseline before chemotherapy (T1), approximately 1 month after chemotherapy but prior to surgery (T2), and after surgery about 9 months post chemotherapy (T3)...
December 2017: Psycho-oncology
Tonya S Orchard, Monica M Gaudier-Diaz, Kellie R Weinhold, A Courtney DeVries
Cancer treatments such as chemotherapy have been an important part of extending survival in women diagnosed with breast cancer. However, chemotherapy can cause potentially toxic side effects in the brain that impair memory, verbal fluency, and processing speed in up to 30% of women treated. Women report that post-chemotherapy cognitive deficits negatively impact quality of life and may last up to ten years after treatment. Mechanisms underlying these cognitive impairments are not fully understood, but emerging evidence suggests that chemotherapy induces structural changes in the brain, produces neuroinflammation, and reduces adult hippocampal neurogenesis...
February 2017: Breast Cancer Research and Treatment
Yin Ting Cheung, Wassim Chemaitilly, Daniel A Mulrooney, Tara M Brinkman, Wei Liu, Pia Banerjee, Deokumar Srivastava, Ching-Hon Pui, Leslie L Robison, Melissa M Hudson, Kevin R Krull
Long-term survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive impairment, as well as compromised hypothalamic-pituitary-adrenal (HPA) function. Dehydroepiandrosterone-sulfate (DHEAS) is an adrenal androgen commonly used as a marker of HPA function. In the general population, a low level of DHEAS has been associated with poorer cognition. At ≥2years post-treatment, we examined the association of DHEAS with attention outcomes in 35 male and 34 female long-term survivors of childhood ALL (mean[standard deviation] age at evaluation 14...
February 2017: Psychoneuroendocrinology
Catarina Rendeiro, Andrew Sheriff, Tushar K Bhattacharya, Joseph V Gogola, Jeffrey H Baxter, Hong Chen, William G Helferich, Edward J Roy, Justin S Rhodes
The negative impact of chemotherapy on cognitive function in cancer patients has gained increasing attention in the last decade. Whilst the short-term acute effects on cognition are expected following chemotherapy, the persistence of such impairments in the long-term is still in question. This is despite clinical evidence indicating cognitive difficulties may persist well beyond treatment and affect quality of life. In the present study, we assessed the long-term (3 months) cognitive impact of chemotherapy in a mouse model intended to mimic the human female post-menopausal population receiving chemotherapy for breast cancer...
December 15, 2016: Behavioural Brain Research
Cory Pierson, Erin Waite, Ben Pyykkonen
BACKGROUND: Long-term neuropsychological deficits associated with pediatric cancers and the related treatments have been consistently reported. Whole brain cranial radiation therapy (CRT) is associated with neurocognitive impairment. As a result, physicians are reticent to use CRT in favor of systemic or intrathecal chemotherapy, which have a less clear impact on cognition. PROCEDURE: The current meta-analysis examined post-treatment neuropsychological performance of children diagnosed with cancer and treated with chemotherapy to better understand the impact of chemotherapy upon cognition...
November 2016: Pediatric Blood & Cancer
Heather Allewelt, Jill El-Khorazaty, Adam Mendizabal, Mahsa Taskindoust, Paul L Martin, Vinod Prasad, Kristin Page, Jean Sanders, Joanne Kurtzberg
Infants and young children who undergo allogeneic cord blood transplantation (CBT) are at increased risk for late effects because of exposure of developing organs to chemotherapy and radiation therapy typically used in transplant conditioning regimens. Busulfan (Bu)-based myeloablative regimens were developed to eliminate radiation exposure in these young children with the hope that late effects would be minimized. We now describe the late effects in 102 consecutive patients surviving a minimum of 5 years (median follow-up, 12...
September 2016: Biology of Blood and Marrow Transplantation
Lauren E Cox, Jason M Ashford, Kellie N Clark, Karen Martin-Elbahesh, Kristina K Hardy, Thomas E Merchant, Robert J Ogg, Sima Jeha, Victoria W Willard, Lu Huang, Hui Zhang, Heather M Conklin
BACKGROUND: Childhood cancer survivors frequently develop working memory (WM) deficits as a result of disease and treatment. Medication-based and therapist-delivered interventions are promising but have limitations. Computerized interventions completed at home may be more appealing for survivors. We evaluated the feasibility and acceptability of a remotely administered, computerized WM intervention (Cogmed) for pediatric cancer survivors using a single-blind, randomized, wait-list control design...
June 2015: Neuro-oncology Practice
Julia Day, David C Gillespie, Alasdair G Rooney, Helen J Bulbeck, Karolis Zienius, Florien Boele, Robin Grant
Neurocognitive deficits are common with brain tumors. If assessed at presentation using detailed neurocognitive tests, problems are detected in 80 % of cases. Neurocognition may be affected by the tumor, its treatment, associated medication, mood, fatigue, and insomnia. Interpretation of neurocognitive problems should be considered in the context of these factors. Early post-operative neurocognitive rehabilitation for brain tumor patients will produce rehabilitation outcomes (e.g., quality of life, improved physical function, subjective neurocognition) equivalent to stroke, multiple sclerosis, and head injury, but the effect size and duration of benefit needs further research...
May 2016: Current Treatment Options in Neurology
Roshan Karunamuni, Hauke Bartsch, Nathan S White, Vitali Moiseenko, Ruben Carmona, Deborah C Marshall, Tyler M Seibert, Carrie R McDonald, Nikdokht Farid, Anithapriya Krishnan, Joshua Kuperman, Loren Mell, James B Brewer, Anders M Dale, Jona A Hattangadi-Gluth
PURPOSE: Radiation-induced cognitive deficits may be mediated by tissue damage to cortical regions. Volumetric changes in cortex can be reliably measured using high-resolution magnetic resonance imaging (MRI). We used these methods to study the association between radiation therapy (RT) dose and change in cortical thickness in high-grade glioma (HGG) patients. METHODS AND MATERIALS: We performed a voxel-wise analysis of MRI from 15 HGG patients who underwent fractionated partial brain RT...
February 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Mi Sook Jung, Min Zhang, Mary K Askren, Marc G Berman, Scott Peltier, Daniel F Hayes, Barbara Therrien, Patricia A Reuter-Lorenz, Bernadine Cimprich
Neural dysfunction and cognitive complaints are associated with chemotherapy for breast cancer although trajectory and contributory factors remain unclear. We prospectively examined neurocognition using fMRI and self-reported cognitive, physical and psychological symptoms in women treated with adjuvant chemotherapy over one year. Patients treated with (n = 28) or without (n = 34) chemotherapy for localized breast cancer and healthy controls (n = 30) performed a Verbal Working Memory Task (VWMT) during fMRI and provided self-reports at baseline (pre-adjuvant treatment), five- (M5) and 12-months (M12)...
February 2017: Brain Imaging and Behavior
Marie-Rose Dwek, Lorna Rixon, Alice Simon, Catherine Hurt, Stanton Newman
BACKGROUND: Research suggests that chemotherapy can cause deficits in both patients' objectively measured and self-reported cognitive abilities which can in turn affect their quality of life (QoL). The majority of research studies have used post-treatment retrospective designs or have not included a control group in prospective cohorts. This has limited the conclusions that can be drawn from the results. There have also been a disproportionate number of studies focussed on women with breast cancer, which has limited the generalisability of the results to other cancer populations...
November 26, 2015: BMC Psychology
J W Y Kam, C A Brenner, T C Handy, L A Boyd, T Liu-Ambrose, H J Lim, S Hayden, K L Campbell
OBJECTIVE: Many breast cancer survivors (BCS) report cognitive problems following chemotherapy, yet controversy remains concerning which cognitive domains are affected. This study investigated a domain crucial to daily function: the ability to maintain attention over time. METHODS: We examined whether BCS who self-reported cognitive problems up to 3 years following cancer treatment (n=19) performed differently from healthy controls (HC, n=12) in a task that required sustained attention...
January 2016: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
Tim A Ahles, Yuelin Li, Brenna C McDonald, Gary N Schwartz, Peter A Kaufman, Gregory J Tsongalis, Jason H Moore, Andrew J Saykin
PURPOSE: This study examined the association of post-treatment changes in cognitive performance, apolipoprotein E (APOE), and smoking in breast cancer patients treated with adjuvant therapy. PARTICIPANTS AND METHODS: Breast cancer patients treated with chemotherapy (N = 55, age = 51.9 ± 7.1, education = 15.7 ± 2.6) were evaluated with a battery of neuropsychological tests prior to chemotherapy and at 1, 6, and 18 months post-chemotherapy. Matched groups of breast cancer patients not exposed to chemotherapy (N = 68, age = 56...
December 2014: Psycho-oncology
Ding-Lieh Liao, Cheng-Yi Huang, Sien Hu, Su-Chen Fang, Chi-Shin Wu, Wei-Ti Chen, Tony Szu-Hsien Lee, Pau-Chung Chen, Chiang-Shan R Li
BACKGROUND: Substance misuse is associated with cognitive dysfunction. We used a stop signal task to examine deficits in cognitive control in individuals with opioid dependence (OD). We examined how response inhibition and post-error slowing are compromised and whether methadone maintenance treatment (MMT), abstinence duration, and psychiatric comorbidity are related to these measures in individuals with OD. METHODS: Two-hundred-and-sixty-four men with OD who were incarcerated at a detention center and abstinent for up to 2 months (n = 108) or at a correctional facility and abstinent for approximately 6 months (n = 156), 65 OD men under MMT at a psychiatric clinic, and 64 age and education matched healthy control (HC) participants were assessed...
2014: PloS One
Djaina Satoer, Evy Visch-Brink, Marion Smits, Alfred Kloet, Caspar Looman, Clemens Dirven, Arnaud Vincent
Preservation of cognition is an important outcome measure in eloquent area glioma surgery. Glioma patients may have pre-operative deficits in one or more cognitive domains which could deteriorate post-operatively. It is assumed that these impairments recover within 3 months; some studies however, still detected cognitive decline. Longer follow-up is necessary to elucidate the conclusive effects of surgery. 45 patients with gliomas (low- and high-grade, but without contrast enhancement at diagnosis) in eloquent areas were assessed pre-operatively, 3 months and 1 year post-operatively with a neuropsychological test-protocol...
January 2014: Journal of Neuro-oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"